Even though high FGF23 levels have been well recognized to be associated with most of the comorbidities of CKD patients, and in particular with cardiovascular disease (CVD), the pathogenic mechanisms by which FGF23 could induce these effects are far from being clear (7–9). This evidence concerns the gene FGF23 and cardiovascular disorder.